Harvard Bioscience acquires CMA Microdialysis' preclinical business
Harvard Bioscience Inc., a global developer of tools for life science research and regenerative medicine, announced last month that it has acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets.
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Related Topics
Published In
Volume 7 - Issue 8 | August 2011
August 2011
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
A streamlined analytical strategy supports reliable plasmid and mRNA quality assessment at every mRNA production stage.
Explore evolving technologies, analytical strategies, and expert guidance supporting high-quality flow cytometry research.
Discover how supercritical fluids expand chromatographic capabilities across diverse analytical challenges.
